American Journal of Clinical Dermatology

Papers
(The TQCC of American Journal of Clinical Dermatology is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
The Skin Microbiome: A New Actor in Inflammatory Acne112
Cutaneous Manifestations of COVID-19: An Evidence-Based Review111
Skin Microbiota and its Interplay with Wound Healing95
Sunscreens and Photoaging: A Review of Current Literature85
Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review79
Rosacea: New Concepts in Classification and Treatment79
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis72
Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib69
Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments66
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study65
Psychosocial Effects of Vitiligo: A Systematic Literature Review64
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program64
Effects of Diet on Acne and Its Response to Treatment61
New and Emerging Targeted Therapies for Vascular Malformations58
Dermatitis Herpetiformis: An Update on Diagnosis and Management55
Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review55
Treatment Options and Goals for Patients with Generalized Pustular Psoriasis55
Skin Microbiome and its Interplay with the Environment54
Erythema Nodosum: A Practical Approach and Diagnostic Algorithm53
Clinical Course and Characteristics of Generalized Pustular Psoriasis51
Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic51
Dermatological Toxicities of Bruton’s Tyrosine Kinase Inhibitors50
Pathophysiology of Generalized Pustular Psoriasis47
A Review of Noninvasive Techniques for Skin Cancer Detection in Dermatology47
Ceramides in Skin Health and Disease: An Update44
The Growing Problem of Antifungal Resistance in Onychomycosis and Other Superficial Mycoses44
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies38
Granuloma Annulare: An Updated Review of Epidemiology, Pathogenesis, and Treatment Options38
Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study38
Cutaneous Leishmaniasis: A 2022 Updated Narrative Review into Diagnosis and Management Developments36
Skin Microbiome as Years Go By36
Deucravacitinib for the Treatment of Psoriatic Disease34
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis34
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma33
New Practical Aspects of Sweet Syndrome33
Microbiota in Rosacea32
Teledermatology During COVID-19: An Updated Review32
New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review31
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)31
Eosinophilic Dermatoses: Recognition and Management28
Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials28
Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study28
50 Years of Topical Retinoids for Acne: Evolution of Treatment28
The Prevalence and Disease Characteristics of Generalized Pustular Psoriasis28
Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial27
Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata27
Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outco26
The Importance of Incorporating Human Factors in the Design and Implementation of Artificial Intelligence for Skin Cancer Diagnosis in the Real World26
Investigational Treatments for Epidermolysis Bullosa26
The Role of the Microbiome and Microbiome-Derived Metabolites in Atopic Dermatitis and Non-Histaminergic Itch26
Impact of Generalized Pustular Psoriasis from the Perspective of People Living with the Condition: Results of an Online Survey25
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)25
Immune-Mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review25
Clinical Disease Measures in Generalized Pustular Psoriasis25
The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma24
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study24
An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions24
Effects of Topical Retinoids on Acne and Post-inflammatory Hyperpigmentation in Patients with Skin of Color: A Clinical Review and Implications for Practice23
Lack of Evidence for an Increased Risk of Severe COVID-19 in Psoriasis Patients on Biologics: A Cohort Study from Northeast Italy23
JAK in the [Black] Box: A Dermatology Perspective on Systemic JAK Inhibitor Safety23
Steroid Phobia: A Review of Prevalence, Risk Factors, and Interventions23
Efficacy of Nonprescription Moisturizers for Atopic Dermatitis: An Updated Review of Clinical Evidence21
A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis20
Diagnosis of Generalized Pustular Psoriasis20
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study20
HLA-Cw1 and Psoriasis20
The Pathogenesis and Management of Acne-Induced Post-inflammatory Hyperpigmentation20
Impact of Facial Atrophic Acne Scars on Quality of Life: A Multi-country Population-Based Survey20
Cigarette Smoking, Alcohol Consumption, and Risk of Alopecia Areata: A Population-Based Cohort Study in Taiwan20
New Topical Therapies for Psoriasis19
What’s New in Topicals for Atopic Dermatitis?19
Fabric Selection in Atopic Dermatitis: An Evidence-Based Review19
Emerging Therapeutic Options for Chronic Pruritus19
A Review of Existing Therapies for Actinic Keratosis: Current Status and Future Directions18
Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System18
Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma18
Behçet Disease: An Update for Dermatologists18
Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review17
Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and Pharmacokinetics17
Vitiligo and Melanoma-Associated Vitiligo: Understanding Their Similarities and Differences17
Dermatologic Laser Side Effects and Complications: Prevention and Management17
DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 202017
Granulomatous Cutaneous Drug Eruptions: A Systematic Review16
Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial16
Treatment Goals in Psoriasis: Which Outcomes Matter Most?16
Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma16
Hypertrophic Scars and Keloids: Advances in Treatment and Review of Established Therapies16
0.020231008529663